Fingerprint
Dive into the research topics of 'Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer
Cheng Jeng Tai, Chin Kwun Pan, Ching Shyang Chen, Chin Sheng Hung, Chih Hsiung Wu, Hung Yi Chiou
- Division of Hematology and Oncology
- Taipei Medical University Hospital
- Department of Surgery
- TMU Research Center of Cancer Translational Medicine
- Division of General Surgery
- TMU Research Center for Organ Transplantation
- Taipei Medical University Shuang Ho Hospital
- School of Public Health
- School of Health Care Administration
- School of Gerontology & Long-Term Care
- Graduate Institute of Clinical Medicine
- Graduate Institute of Medical Humanities
- Master Program in Applied Epidemiology
- Master Program in Global Health and Health Security
- Ph.D. Program in Global Health and Health Security
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery
- Ph.D. Program in Medical Neuroscience
- Master Program in Clinical Genomics and Proteomics
Research output: Contribution to journal › Article › peer-review
7
Citations
(Scopus)